A small randomized pilot trial found that one week of carbidopa-levodopa treatment showed a strong trend toward improved walking parameters in older adults with mild parkinsonian signs but no clinical Parkinson's disease. Participants receiving active treatment (carbidopa pretreatment for three days followed by carbidopa-levodopa for seven days) demonstrated improvements in cadence and step duration compared to placebo controls, with a beta coefficient of 0.506 approaching statistical significance (p=0.076). This finding taps into emerging recognition that age-related dopaminergic decline contributes to gait deterioration even before clinical Parkinson's manifests. The approach could represent a preventive intervention for mobility decline in aging, potentially preserving independence and reducing fall risk. However, significant limitations temper these promising results. The pilot study appears quite small, lacks reported sample sizes, and the primary outcome narrowly missed statistical significance. Long-term safety of levodopa in non-Parkinsonian older adults remains unexplored, including risks of dyskinesia or tolerance. As an unreviewed preprint, these results require peer review and replication in larger cohorts before clinical application. The research represents an intriguing but preliminary step toward pharmacological gait enhancement in healthy aging.